Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: Responders versus nonresponders

Table 1 Patient characteristics

	Ulcerative colitis	Crohn's disease
	(n = 22)	(n = 24)
Sex (M/F)	13/9	14/10
Age (yr) (mean and range)	41 (18 – 78)	42 (20 – 69)
Duration (yr) (mean and range)	7.4 (0 – 30)	9 (0 – 28)
Smoking habits (n)
Active	2	3
Former	6	8
Non-smoker	7	9
Unknown	7	4
Concomitant medication (n)
Aminosalicylates	18	12
Local steroids	6	2
Site of disease
Ileocolonic	24
Rectum	3
Proctosigmoiditis	6
Extensive/total	13
Disease activity index
(mean and range)	9.4 (5 – 12)
Harvey-Bradshaw index
(mean and range)		14.9 (4 – 29)
Endoscopic score
(mean and range)	2.2 (1-3)	2.1 (0-3)

Table 2 Disease activity index, UC patients

t/d	All	Responder	Non-responder	Operated(
	(n = 22)	(n = 10)	(n = 12)	n = 5)
1	9.4 (5-12)	9.5 (5-12)	9.4 (5-12)	11.2 (10-12)
3	7.4 (2-12)	7.1 (2-10)	7.6 (5-12)	12
7	5.7 (2-9)	4.8 (2-7)	7.2 (5-9)	NA
28	2.5 (0-8)	0.8 (0-2)	5 (3-8)	NA

Responder (DAI 2); non-responder (DAI ≥ 3).

Table 3 Harvey-Bradshaw index, CD patients

t/d	All	Responder	Non-responder	Operated
	(n = 24)	(n = 8)	(n = 16)	(n = 7)
1	14.9 (4 - 29)	12.8 (4 - 26)	15.9 (9 - 29)	16.9 (11 - 29)
3	11.2 (2 - 22)	7.9 (2 - 13)	12.9 (2 - 22)	16.2 (11 - 22)
7	7.7 (1 - 19)	5.8 (1 - 19)	9.6 (2 - 13)	11.5 (10 - 13)
28	4.2 (1 - 9)	1.9 (1 - 3)	6.9 (4 - 9)	NA

Responder (HBI ≤ 4); non-responder (HBI ≥ 5).